Typhoid fever remains an important public health priority, particularly in developing countries, with an estimated 16 million new cases annually and 600,000 deaths (17, 21) . The appearance of antibiotic-resistant strains of Salmonella enterica serovar Typhi, the causative agent of typhoid fever, has added new urgency for the development of improved typhoid vaccines. New-generation attenuated serovar Typhi vaccine strains have the potential to become the preferred public health tool to immunize against typhoid fever because of their ability to elicit long-lasting protective systemic and mucosal immune responses. In addition, significant efforts have been focused in recent years on the use of attenuated serovar Typhi vaccines as carriers of foreign antigens to deliver foreign genes because of their ability to gain access to dendritic cells (51, 52) and deliver antigens or DNA coding for the antigens (12, 31, 32) . These characteristics make the use of Salmonella live vectors particularly attractive for mass immunization programs. Moreover, live attenuated serovar Typhi vaccines are expected to have relatively low manufacturing costs compared to many other types of vaccines. CD8 ϩ T cells might play an important role in host defense against serovar Typhi by several effector mechanisms, including lysis of infected cells and gamma interferon (IFN-␥) secretion (35, 36, 44, 45) . These CD8 ϩ T cells recognize antigenic peptides bound to self-major histocompatibility complex via T-cell antigen receptor (TCR) (26, 48) on the surface of infected cells. The TCR on most peripheral T cells is a heterodimeric molecule, composed of ␣ (V␣) and ␤ (V␤) chains (7) . Functionally, V␤ has been associated with the antigen recognition process, and specific recognition of peptide results in the clonal expansion of a subset of V␤ antigen-specific T cells (7, 26) . Thus, direct examination of TCR V␤ specificities has been used to identify and track oligoclonal antigen-specific T-cell responses during infection and after immunization (1, 14, 30) . Approximately 60 TCR V␤ gene segments are known in humans (30) . TCR V␤ usage has been studied in various systems, and either broad or restricted patterns have been identified in a number of areas, including autoimmunity (29, 53) , response to viral (10, 25, 40, 42) or bacterial (8, 11, 16, 27) antigens, and tumor immunity (22) . The induction of strong, long-lived immunologic T-and Bcell memory responses is of paramount importance in the development of effective vaccines. Thus, in the present study, we analyzed the TCR V␤ gene usage of specific CD8 ϩ T cells from healthy adults 5 to 40 months after oral immunization with serovar Typhi strain Ty21a, the only licensed attenuated typhoid vaccine, to gain further insights into the clonality and characteristics of T-cell responses to serovar Typhi. Although the responses were oligoclonal, we observed that CD8 ϩ T cells from several V␤ families participated in the anti-serovar Typhi response. Moreover, we studied the induction of memory Tcell subsets and the homing potential of these cells. The specificity of the expanded cell subsets was demonstrated by functional assays on V␤ sorted cells and on clones. Moreover, we observed that V␤ serovar Typhi-specific CD8 ϩ T cells express expression of surface homing and/or effector memory molecules was assessed in these T-cell clones by eight-color flow cytometry (MoFlo). The following MAbs (coupled to the indicated fluorochromes) were used: integrin ␣4␤7 (clone ACT-1) was kindly provided by W. Newman, Leukosite, Cambridge, MA, and conjugated to Alexa 488 using an Alexa 488 labeling kit (Molecular Probes); CD27-PE (clone M-T271); CD62L-PE-Cy5 (clone Dreg-56); CCR7-PE-Cy7 (clone 3D12) and CD8-APC-Cy7 (clone Sk1) (BD Pharmingen); CD45RO-ECD (clone UCHL-1) and CD103-biotin (clone 2G5) (Beckman-Coulter); and CCR9-APC (clone 112509; R&D Systems, Minneapolis, MN). Alexa 405-streptavidin was purchased from Molecular Probes. Cytotoxicity (chromium release test). As previously described in detail, cytotoxicity against uninfected or serovar Typhi-infected targets was determined by using a 4-h 51 Cr release assay (34) (35) (36) 44) . Specific cytotoxicity mediated by effector cells was calculated by substracting the lysis of uninfected targets from the lysis of serovar Typhi-infected targets. Lysis of noninfected targets was generally less than 10%. The cutoff for positive responses in CTL assays was defined as Ͼ10% specific cytotoxicity (34) (35) (36) 44) .
IFN-␥ ELISPOT assays. The human IFN-␥ ELISPOT assay was carried out as previously described (34) (35) (36) . Briefly, PBMC from immunized volunteers were incubated with uninfected or serovar Typhi-infected stimulator cells. Effector cells cultured without stimulator cells or with CD3/CD28 beads (0.6 l/ml; Dynal) were used as negative and positive controls, respectively. After 16 h, cultures were assayed for IFN-␥ by ELISPOT. Anti-IFN-␥ (5 g/ml, clone 2G1; Endogen, Woburn, MA) and biotinylated anti-IFN-␥ (2 g/ml, clone B133.5; Endogen) MAbs were used as capture and detection reagents, respectively. Complexes were detected by incubation with avidin-peroxidase conjugate (Sigma), and TrueBlue reagent (KPL) was used as a substrate. Each sample was tested in triplicate. Spots were enumerated using a stereomicroscope. Net frequencies were calculated as previously described (34) (35) (36) . The cutoff for ELIS-POT assays was established as the frequency of IFN-␥ spot-forming cells/10 6 PBMC in cocultures of effectors with noninfected targets plus 3 standard errors (SE).
Statistical analysis. All tests were performed using SigmaStat software (version 3.0; SPSS Science software products, Chicago, IL). P values that were Ͻ0.05 were considered significant. 
RESULTS
Generation of serovar Typhi-specific polyclonal cell lines for V␤ analysis. Our initial approach to evaluating the V␤ repertoire of specific T cells elicited in humans following immunization with the attenuated Ty21a typhoid vaccine involved the enrichment of serovar Typhi-specific T cells by repeated cycles of in vitro restimulation with serovar Typhi-infected polyclonal autologous blasts. We have previously reported the use of serovar Typhi-specific T-cell lines following one cycle of in vitro stimulation with serovar Typhi-infected autologous polyclonal blasts to demonstrate specific cytotoxic activity and IFN-␥ production in clinical trials of attenuated serovar Typhi oral live vector vaccines (34) (35) (36) . In the present studies, serovar Typhi-specific polyclonal cell lines from three Ty21a typhoid vaccinees generated following one cycle of in vitro stimulation were further expanded by weekly restimulation with irradiated autologous serovar Typhi-infected blasts for up to 3 weeks before specificity and TCR V␤ repertoire analysis. Aliquots of these effector cells were frozen weekly before each new restimulation, and the phenotype of these cell lines was determined. The specificity of these cell lines was evaluated by measuring their ability to secrete IFN-␥ and to kill serovar Typhi-infected targets.
Secretion of IFN-␥ by effector cells in response to stimulation with serovar Typhi-infected targets was measured by ELISPOT in ex vivo PBMC and in polyclonal cell lines after one, two, and three cycles of in vitro restimulation. Marked increases in the frequency of IFN-␥-secreting cells in response to stimulation with serovar Typhi-infected targets were observed. The largest increase of IFN-␥ production occurred after one cycle of in vitro restimulation. Similarities in the levels of IFN-␥ production following two and three cycles of in vitro restimulation suggest a stabilization of these responses with continued in vitro stimulation. Compared with preimmunization levels without in vitro restimulation, postimmunization PBMC without in vitro restimulation showed a 3-fold increase, while polyclonal cell lines showed an average 35-fold increase in serovar Typhi-responsive cells (63-, 24-, and 19-fold after one, two, and three cycles of in vitro restimulation, respectively) (Fig. 1) . This corresponds to 0.3 to 1% of the total cell population (2,853 to 9,640 spots/10 6 cells in these polyclonal cell lines).
51 Cr release assays and correlation with IFN-␥-secreting effector T-cell populations. Cytolytic function of the polyclonally expanded cell lines was measured by standard 51 Cr release assays. After 3 weeks of in vitro restimulation with autologous serovar Typhi-infected targets, we observed that these cell lines maintain high levels of CTL activity against serovar Typhi-infected targets. As shown in Fig. 2 , similar results were obtained in volunteers 1 and 2. Consistent with our previous results, ex vivo PBMC from both volunteers were unable to lyse autologous blasts infected with serovar Typhi (35, 36) . However, both volunteers showed increased levels of cytotoxic activity after in vitro restimulation. Although CTL activity is at best semiquantitative, it is important to note that, as observed with IFN-␥ production, the highest increase of the cytotoxicity levels occurred after one in vitro restimulation followed by stabilization after two and three cycles of in vitro restimulation (e.g., volunteer 2 exhibited 33, 17, and 17% of specific lysis at an effector-to-target cell [E:T] ratio of 3:1 after one, two, and three in vitro restimulation cycles, respectively). Moreover, as we have previously described (35), when we compared the results obtained by ELISPOT with those obtained by 51 Cr release assays, a positive correlation (R 2 ϭ 0.910, P Ͻ 0.046) was observed between the frequencies of serovar Typhi antigen-responsive cells, as evidenced by IFN-␥ production and the cytotoxic activity of these cell lines at E:T ratios of 3:1 (data not shown).
Taken together, the results from IFN-␥ ELISPOT and CTL assays clearly show that the polyclonal cell lines remain functional after repeated cycles of specific antigenic stimulation. 51 Cr release assays. The dashed line represents the cutoff for positive 51 Cr release assays as described in the text.
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Characterization of the effector population. We next investigated which cell populations in PBMC from immunized volunteers were preferentially expanded after several cycles of in vitro restimulation with serovar Typhi-infected autologous blasts. In agreement with previous results using a similar system (34-36), a major expansion in CD8 ϩ T-cell populations, as determined by flow cytometry, occurred during in vitro restimulations. The percentage of CD8 ϩ T-cell populations increased progressively after each additional in vitro restimulation (e.g., 26, 44, and 63% after one, two, and three cycles of in vitro restimulation, respectively). These increases were accompanied by concomitant decreases in the percentage of CD4 ϩ cells at the same time points (28, 13 , and 9% after one, two, and three cycles of in vitro restimulation, respectively) (Fig. 3) . No changes were observed in the percentage of NK (CD56 ϩ ) or T cells bearing ␥/␦ T-cell receptors (Fig. 3) .
To further characterize the composition of polyclonal cell lines after in vitro restimulation, the proportion of cells expressing molecules involved in T-cell activation and those associated with memory effector T cells in populations following three cycles of in vitro expansion were compared to those present in PBMC without in vitro restimulation. To this end, PBMC from Ty21a vaccinees ex vivo or cocultured with stimulators for up to 3 weeks were stained with MAbs to CD3, CD4, CD8, CD56, CD25, CD28, CD38, CD45RO, CD62L, and HLA-DR and analyzed by multicolor flow cytometry. The results are shown in Table 2 . Of the various CD3 ϩ CD8 ϩ cell subpopulations expressing CD45RO ϩ , a T-cell memory marker, only the percentages of CD38 ϩ and HLA-DR ϩ differed significantly between ex vivo and in vitro-restimulated PBMC. Five-color flow cytometric analysis showed that in vitro-expanded CD3 ϩ CD8 ϩ CD45RO ϩ T cells contained a greater proportion of cells bearing activation molecules (HLA-DR, 97%; CD38 ϩ , 39%) than did the initial ex vivo population (HLA-DR, 24%; CD38 ϩ , 9%). Smaller increases were also observed in the percentages of CD3 ϩ CD4 ϩ CD45RO ϩ populations coexpressing HLA-DR and CD38 after each cycle of restimulation (Table 2 ). Of note is that no major differences were observed in the expression of CD62L and CD28 in either cell population (Table 2) .
Taken together, the results from the functional assays and the analysis of surface expression of activation/memory molecules suggest that activated CD8 ϩ T cells coexpressing memory markers remain functional after several rounds of in vitro stimulation and are therefore appropriate for studying the TCR V␤ repertoire induced by immunization of volunteers with the Ty21a typhoid vaccine.
Flow cytometric V␤ analysis in polyclonal cell lines. Following functional validation and characterization of the polyclonal cell lines, we next evaluated the TCR V␤ repertoire of these populations. First, we examined whether CD8 ϩ T cells with a broad TCR V␤ repertoire or a limited selected repertoire are involved in the host's serovar Typhi response after administration of the Ty21a typhoid vaccine. To this end, we studied the TCR V␤ usage of these cell lines by flow cytometry using a panel of 24 MAbs which cover ϳ60% of the known specificities (47) .
Five-color cytofluorometric analysis was performed to determine whether CD4 ϩ or CD8 ϩ T cells of defined V␤ were preferentially expanded by in vitro restimulation. Changes above the mean plus 3 SE of the ex vivo effector cells (controls) were defined as being increased. Although TCR V␤ diversity varied greatly from volunteer to volunteer, we observed the oligoclonal expansion of particular V␤ subsets in each individ- nization levels without in vitro restimulation (3.0%), whereas CD4 ϩ V␤ 17 ϩ cells did not change significantly over time (5.8, 5.4, 5.4, and 5.8% ex vivo and after one, two, and three restimulations, respectively) (data not shown). In volunteer 2, a major increase in the percentage of CD8 ϩ T cells expressing TCR V␤ 2 was found even after a single cycle of in vitro restimulation (14.3%), and it continued to rise after three successive cycles of in vitro restimulation (20.5%), compared to postimmunization levels without in vitro restimulation (4.1%) (Fig. 4) . CD4
ϩ V␤ 2 ϩ cells did not change significantly over time (4.2, 6.3, 5.3, and 6.5% ex vivo and after one, two, and three restimulations, respectively) (data not shown). Taken together, the most prominent changes were observed in the V␤ 2, 3, 5.1, 14, 16, and 17 families. Increases in V␤ 2, V␤ 5.1, and V␤ 17 were observed in both volunteer 1 and volunteer 2. Of note is that although in volunteer 3 the V␤ 2 and V␤ 17 changes did not reach the mean percentage plus 3 SE of ex vivo effector cells used as a cutoff level of positivity, increases of 5 to 18 times over the values observed ex vivo without restimulation were observed after the first and second restimulations (i.e., for V␤ 2, 0.1, 1.43, and 1.85% and for V␤ 17, 0.19, 1.02, and 2.43% of positive cells were observed ex vivo, after one cycle, and after two cycles, respectively).
It is important to note that except for the overrepresentation of V␤ 13.2 in volunteer 2 and V␤ 12 in volunteer 3, the reported distributions of V␤ usage observed in ex vivo effectors (controls) are comparable to the V␤ usage previously reported for healthy controls ( (Fig. 5A) . The CTL activity of sorted as well as unsorted populations was measured by 51 Cr release assays against serovar Typhi-infected autologous blasts. More than 10% specific lysis was observed in both sorted and unsorted PBMC at an E:T ratio of 3:1 (Fig. 5B ). These results demonstrate that both TCR V␤ 2 ϩ CD3 ϩ CD8 ϩ and TCR V␤ 2 Ϫ CD3 ϩ CD8 ϩ populations are functional and specific for serovar Typhi-infected targets. Moreover, these results also indicate that TCR V␤ specificities other than V␤ 2 are also able to mediate CTL activity. Taken together, these observations support the notion that more than one TCR V␤ family is involved in the host's response to serovar Typhi after vaccination with the Ty21a typhoid vaccine.
TCR V␤ repertoire and expression of molecules involved in homing and effector and memory function in T-cell clones specific for serovar Typhi antigens. To confirm the V␤ usage of T cells elicited by immunization, as well as to identify additional TCR V␤ specificities that could be involved in specific responses to serovar Typhi, T-cell clones were derived from PBMC from volunteers 2 and 3. T-cell clones were derived by limiting dilution, as described in Materials and Methods, and established cell lines were examined for TCR V␤ usage, a procedure that also helped to confirm the clonality of the populations. The functional activity of these T-cell clones was examined by specific cytotoxicity and frequency of IFN-␥-secreting cells against serovar Typhi-infected targets by 51 Cr release and IFN-␥ ELISPOT assays, respectively. Figure 6 summarizes the IFN-␥ production, cytotoxicity, and TCR V␤ usage of eight CD8 ϩ T-cell clones. In ELISPOT assays, two CD4 ϩ T-cell clones (TP1-24 and TS1-24) were used as negative controls. The clones that either killed infected targets or produced IFN-␥ were considered responders. Among the six responder CD8 ϩ T-cell clones (TP1-6, TP1-16, TP1-38, TP1-39, TP1-40, and TS1-27), one clone expressed V␤ 7.2, one expressed V␤ 3, and two expressed V␤ 16. For two clones (TP1-16 and TP1-38), no reactivity was observed with any of the anti-TCR V␤ MAbs in our panel. This is likely the result of the lack of a MAb for the appropriate V␤ specificity in the panel, which in the case of volunteer 3 identified 61% of the TCR V␤ repertoire. Of note is that while some T-cell clones (e.g., TP1-38 and TS1-27) exhibited both CTL and IFN-␥ production capabilities, other clones (e.g., TP1-16) were only either cytotoxic or able to produce IFN-␥, suggesting heterogeneity in the effector function of different T-cell subpopulations following immunization with serovar Typhi vaccines.
It is widely recognized that oral immunization induces effector memory cells carrying distinct homing receptors (e.g., integrin ␣4␤7, CCR9, and CD103) that might endow the effector cells with the capability to migrate preferentially to the gut (13, 18, 33, 39) . Thus, it was important to assess whether these molecules are present on the T-cell clones from volunteers immunized orally with the Ty21a typhoid vaccine described above. Moreover, it was also important to determine whether these T-cell clones exhibit an effector memory phenotype. To this end, clones were stained with MAbs to CD8, CD27, CCR7, CD45RO, CD62L, ␣4␤7, CCR9, and CD103 and analyzed by eight-color flow cytometry. Despite the observed functional and TCR V␤ usage differences among these clones, there were remarkable similarities in their phenotype 
Ϫ sorted cell populations were used as effector cells against serovar Typhi-infected autologous blasts, and the cytotoxicity was measured by 51 Cr release assays. Bars represent the mean percent specific cytotoxicity observed for each target at an E:T ratio of 3:1. Error bars show the standard deviations of triplicate cultures. The dashed line represents the cutoff for positive 51 Cr release assays. and expression of homing molecules. All serovar Typhi-specific T-cell clones were found to be CCR7 Ϫ CD27 Ϫ CD45RO ϩ CD62L low , i.e., exhibit an effector memory phenotype (9, 37). Moreover, clones expressed high levels of integrin ␣4␤7 (Ͼ92%), moderate levels of CCR9 (8 to 35%), and low levels of CD103 (1 to 8%) (Fig. 7) . Taken together, these results confirm an oligoclonal expansion of V␤ serovar Typhi-specific CD8 ϩ T cells, which have a phenotype consistent with T effector memory cells with preferential gut homing potential.
DISCUSSION
In the present study, we evaluated the TCR V␤ specificities of CD8 ϩ T cells from three healthy adults orally immunized with the attenuated serovar Typhi Ty21a strain typhoid vaccine. PBMC from Ty21a typhoid vaccinees were expanded by weekly restimulation with irradiated autologous serovar Typhiinfected blasts for up to 3 weeks and used as effector cells. We found that CD8 ϩ T cells from several V␤ families participated in the anti-serovar Typhi response. Although TCR V␤ usage varied from one volunteer to another, our results are consistent with an oligoclonal V␤ subset expansion in each volunteer (V␤ 2, 5.1, 8, 17, and 22 in volunteer 1; V␤ 1, 2, 5.1, 14, 17 , and 22 in volunteer 2; and V␤ 3, 8, 14, and 16 in volunteer 3). Moreover, we observed that these subsets were antigen specific, as shown by functional assays on cells sorted based on their V␤ expression and on T-cell clones. Furthermore, we show that V␤ serovar Typhi-specific CD8 ϩ T cells exhibit a phenotype consistent with effector memory cells with gut homing potential.
Restricted T-cell V␤ repertoires have been shown in infections with bacteria, including Streptococcus (27, 46) , Staphylococcus (8, 38) , Mycobacterium tuberculosis (11, 28) , Listeria (15) , and Shigella (16) . Although the TCR V␤ repertoire observed with these pathogens was somewhat diverse, TCR V␤ 2 and V␤ 3 usage appears to be favored. The observation in our studies with volunteers immunized with serovar Typhi that V␤ 2 and V␤ 3 specificities were preferentially used appears to support this notion. Interestingly, a study with Shigella (16), a pathogen that shares 80% homology with serovar Typhi, showed a pattern of TCR V␤ usage surprisingly similar to that observed in our expanded T-cell lines. Despite the fact that in this study a limited panel composed of just nine MAbs to different TCR V␤ specificities was used (compared to the 24 V␤ specificities evaluated in our study), the increases in TCR V␤ 2, V␤ 3, V␤ 5.1, V␤ 13.6, and V␤ 17 reported were re- Taken together, these observations support the notion that it is likely that T-cell responses against some, if not most, bacteria might be oligoclonal in nature and use a relatively restricted set of TCR V␤ specificities. The aim of the studies presented in this paper was to analyze the TCR V␤ usage in healthy adults 5 to 40 months after oral immunization with serovar Typhi strain Ty21a to evaluate the persistence of serovar Typhi-specific responses over time. Because the postimmunization specimens were collected long after the T-cell memory contraction phase took place, it is not surprising that we did not observe differences when comparing the ex vivo TCR V␤ usage before and after immunization in two of the volunteers (volunteers 1 and 2) (data not shown). To overcome this difficulty, we evaluated the V␤ repertoire of specific T cells after repeated cycles of in vitro restimulation with serovar Typhi-infected polyclonal autologous blasts. Although this procedure does not allow us to estimate their frequency in vivo, available evidence with other gram-negative bacteria suggests that it should not have negatively affected the identification of at least some of the different specificities elicited by immunization with serovar Typhi. In this context, although some reports studying virus-specific CTL populations showed that in vitro expansion of lymphocytes can introduce a significant bias in TCR usage (41), a previous study in Shigella (16) showed that the in vitro TCR V␤ repertoire was similar to that observed in vivo. By comparing the in vivo and in vitro changes in the TCR V␤ repertoire over time, the authors concluded that the in vitro response induced by Shigella antigens showed a TCR V␤ distribution similar to that observed in vivo. Interestingly, the changes in TCR V␤ usage observed in that study peaked 8 to 11 days after the onset of disease, returning to baseline levels after 30 days. Islam et al. hypothesized that this kinetics was either due to homing of circulating cells to the gut-associated lymphoid tissues or, alternatively, due to apoptotic cell death (16) . Interestingly, in the present study, we also observed that the expansion of some V␤ specificities after one cycle of in vitro restimulation (about day 8) was followed by contraction and/or stabilization of these same V␤ specificities during the next rounds of in vitro restimulation. Of note is that after one cycle of in vitro restimulation, we observed stabilization in the cytotoxicity of and IFN-␥ production by serovar Typhi-specific CD8 ϩ T cells, despite an increase in the percentage of CD8 ϩ T cells up to the third week of restimulation. These results may reflect the loss of some clones (e.g., by apoptosis death or loss of specificity) and their replacement by others following successive in vitro restimulations, a phenomenon frequently observed with T-cell clones. Finally, it should be emphasized that it is presently not possible (50) , the presence of variables during in vitro expansion that are difficult to control, and technological limitations. These limitations include the following: (i) in most cases, TCR V␤ antigen-specific T-cell precursors exist at frequencies below the level of detection by standard ex vivo methodologies, e.g., tetrameric complexes; (ii) even in the case of high in vivo frequency of certain TCR V␤ antigen-specific T-cell precursors, T-cell stimulation may require a particular TCR conformation or conformational change that is found only on the surface of certain presenting cells (6); and (iii) while Bouneaud et al. (2) showed that nearly half of their tetramer-binding T cells were unable to expand in response to physiological levels of antigen, Bullock et al. (4) showed that the reverse may also occur, i.e., T cells that show strong functional reactivity towards target cells may not necessarily be detected ex vivo by major histocompatibility complex-tetramer staining.
It is well established that lymphocytes continuously recirculate from peripheral blood to secondary lymphoid tissues (3). This recirculation is essential for homing of effector memory cells, which do not express CCR7 or CD27 and are mostly CD45RO ϩ CD62L low , to effector sites (9, 13, 37) . Serovar Typhi cells are highly invasive bacteria that rapidly and efficiently colonize and invade the mucosa of the small intestine following ingestion (19) . Thus, in Salmonella infections, it is likely that specific memory effector T cells in circulation will be homing to effector sites in the gut where they might encounter Salmonella antigens. Selective homing of effector memory cells to the lamina propria of the small intestine is driven, to a large extent, by the expression of the integrin ␣4␤7, which binds MAdCAM-1, a molecule selectively expressed in the venules of normal and inflamed intestinal endothelium (5) . In this regard, a study by Lundin et al. has shown that immunization with the Ty21a typhoid vaccine induces antigen-specific T cells that preferentially express integrin ␣4␤7 and are found in circulation up to 21 days following immunization (23) . However, other molecules have also recently been shown to participate in this homing process. For example, expression of CCR9 in subsets of circulating integrin ␣4␤7 hi or ␣E␤7 (CD103) lymphocytes plays an important role in homing of these cells to the small intestine (13, 18, 43) . Thus, it was important to evaluate the patterns of expression of these homing molecules in V␤ serovar Typhi-specific CD8 ϩ T cells. We observed that T-cell clones, regardless of their TCR V␤ usage, exhibited an effector memory phenotype (i.e., CCR7 Ϫ CD27 Ϫ CD45RO ϩ CD62L low ) and coexpressed high levels of integrin ␣4␤7, intermediate levels of CCR9, and low levels of CD103 gut homing molecules, suggesting that these TCR V␤-specific clones have the potential to home to the gut-associated lymphoid tissues.
It has been reported that only a few V␤ families predominate in the human gut mucosa (1), with the most frequent being V␤ 1, V␤ 2, V␤ 3, and V␤ 6 (49). Because we studied peripheral blood, we have to consider the possibility that our observations might not reflect the full spectrum of TCR V␤ usage by serovar Typhi-specific CD8 ϩ T cells in the gut microenvironment in vivo. However, our observations that (i) serovar Typhi-specific CD8 ϩ T cells from Ty21a vaccinees exhibited gut homing potential and (ii) except for V␤ 6, which was not present in our MAb panel, we observed all other V␤ specificities (V␤ 1, V␤ 2, and V␤ 3, with the most prominent changes in V␤ 2 and V␤ 3) support the contention that the TCR V␤ usage that we observed in circulation might reflect to a large extent that found in the gut mucosa microenvironment.
Taken together, our observations suggest that the CD8 ϩ effector memory T-cell subpopulations of the restricted TCR V␤ specificities described in this paper are likely to be the effector cells that mediate anti-serovar Typhi long-term cellmediated immune responses in the local microenvironment of the gut mucosa following oral immunization with attenuated strains of serovar Typhi.
